Secukinumab/ustekinumab

Secukinumab/ustekinumab Reactions 1680, p304 - 2 Dec 2017 Paradoxical psoriasis: 2 case reports In a monocentric retrospective observational study of five patients, a 37-year-old woman and a 46-year-old woman developed paradoxical psoriasis during treatment with ustekinumab (1 patient) or secukinumab (1 patient) [routes and outcomes not stated]. Patient 1: A 37-year-old woman, who was diagnosed with SAPHO syndrome characterised by palmoplantar pustulosis since three years, received treatment with ustekinumab 90mg. Subsequently, she developed paradoxical psoriasis. After six months of the treatment, ustekinumab was discontinued. Patient 2: A 46-year-old woman, who was diagnosed with SAPHO syndrome characterised by palmoplantar pustulosis since five years, received treatment with secukinumab 150mg. Subsequently, she developed paradoxical psoriasis. After three months of the treatment, secukinumab was discontinued. Author comment: "No particular safety concerns were reported, except cases of paradoxical psoriasis flare(contributing to discontinuation of treatment) in one under ustekinumab, and the other case under secukinumab." Wendling D, et al. IL-23/Th17 targeted therapies in SAPHO syndrome. A case series. Joint Bone Spine 84: 733-735, No. 6, Dec 2017. Available from: URL: https://doi.org/10.1016/j.jbspin.2017.05.016 - France 803284087 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Secukinumab/ustekinumab

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/secukinumab-ustekinumab-a0i7JA5Koa
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39235-4
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p304 - 2 Dec 2017 Paradoxical psoriasis: 2 case reports In a monocentric retrospective observational study of five patients, a 37-year-old woman and a 46-year-old woman developed paradoxical psoriasis during treatment with ustekinumab (1 patient) or secukinumab (1 patient) [routes and outcomes not stated]. Patient 1: A 37-year-old woman, who was diagnosed with SAPHO syndrome characterised by palmoplantar pustulosis since three years, received treatment with ustekinumab 90mg. Subsequently, she developed paradoxical psoriasis. After six months of the treatment, ustekinumab was discontinued. Patient 2: A 46-year-old woman, who was diagnosed with SAPHO syndrome characterised by palmoplantar pustulosis since five years, received treatment with secukinumab 150mg. Subsequently, she developed paradoxical psoriasis. After three months of the treatment, secukinumab was discontinued. Author comment: "No particular safety concerns were reported, except cases of paradoxical psoriasis flare(contributing to discontinuation of treatment) in one under ustekinumab, and the other case under secukinumab." Wendling D, et al. IL-23/Th17 targeted therapies in SAPHO syndrome. A case series. Joint Bone Spine 84: 733-735, No. 6, Dec 2017. Available from: URL: https://doi.org/10.1016/j.jbspin.2017.05.016 - France 803284087 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve Freelancer

DeepDyve Pro

Price
FREE
$49/month

$360/year
Save searches from
Google Scholar,
PubMed
Create lists to
organize your research
Export lists, citations
Read DeepDyve articles
Abstract access only
Unlimited access to over
18 million full-text articles
Print
20 pages/month
PDF Discount
20% off